Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Immune-adjuvant Effect in CLL
NCT01924169Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in hypogammaglobulinemia, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2014; status: terminated.
02
Drugs
lenalidomide
03
Conditions
hypogammaglobulinemia
Beyond the preview
Go deeper on NCT01924169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01924169.